Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos（t）ide analogues

• Published in: 世界胃肠病学杂志：英文版 Vol. 18; no. 48; pp. 7149 - 7157
• Main Author: Zhuo-Lun Song Yu-Jun Cui Wei-Ping Zheng Da-Hong Teng Hong Zheng
• Format: Journal Article
• Language: English
• Published: 2012
• Subjects: 临床应用; 抗HBV; 抗病毒治疗; 核苷; 类似物; 耐药性; 肝炎病毒; 诊断
• ISSN: 1007-9327; 2219-2840

Nucleos（t）ide analogues（NA） are a breakthrough in the treatment and management of chronic hepatitis B.NA could suppress the replication of hepatitis B virus（HBV） and control the progression of the disease.However,drug resistance caused by their long-term use becomes a practical problem,which influences the long-term outcomes in patients.Liver transplantation is the only choice for patients with HBV-related end-stage liver disease.But,the recurrence of HBV after transplantation often caused by the development of drug resistance leads to unfavorable outcomes for the recipients.Recently,the multi-drug resistance（MDR） has become a common issue raised due to the development and clinical application of a variety of NA.This may complicate the antiviral therapy and bring poorly prognostic outcomes.Although clinical evidence has suggested that combination therapy with different NA could effectively reduce the viral load in patients with MDR,the advent of new antiviral agents with high potency and high genetic barrier to resistance brings hope to antiviral therapy.The future of HBV researches relies on how toprevent the MDR occurrence and develop reasonable and effective treatment strategies.This review focuses on the diagnostic and therapeutic progress in MDR caused by the anti-HBV NA and describes some new research progress in this field.